Effects of adenosine triphosphate on vandetanib induced skin damage in rats

ArticleAçık Erişim

Özet

Purpose: Vandetanib is a wide spectrum tyrosine kinase inhibitor used for the treatment of metastatic medullary thyroid cancer (MTC) and various other cancer types. Although it is usually well-tolerated ıt has been linked to a variety of severe dermatologic reactions. Our study aimed was to investigate adenosine 5′-triphosphate (ATP) on vandetanib-induced skin damage. Materials and methods: A total number of 18 rats were divided into three equal groups as vandetanib group (VDB), vandetanib plus ATP group (VAT), and healthy group (HG); 25 mg/kg ATP was injected intraperitoneally (ip) to the VAT group. Normal saline was given to the HG and VDB groups as solvent via intraperitoneally. One hour later, 25 mg/kg vandetanib was applied orally via an orogastric catheter in the VAT and VDB groups. This procedure was repeated once daily for 4 weeks. After that period, all animals were sacrificed and their skin tissues removed. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS) levels in rats’ skin tissues were evaluated with histopathological analyses. Results: MDA and TOS levels measured higher in the VDB group compared to the VAT and HG groups (p < 0.001). tGSH and TAS levels of the VDB group measured lower than the VAT and HG groups (p < 0.001). The structure and morphology of skin tissue were normal in the control group. In the VDB group, skin tissue damage with thinner epitelium, ruptured and degenerated hair follicles, abnormal accumulation of abnormal keratin on the epithelium and oedematous areas in the dermis was observed. In the VAT group, these findings were significantly improved. Conclusion: We demonstrated that adenosine triphosphate can prevent vandetanib-induced skin toxicity in rats for the first time. The promising results denote that further studies testing this agent in other animal models and in humans are warranted. © 2020 Informa UK Limited, trading as Taylor & Francis Group.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13540Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorAkagunduz, Baran
dc.contributor.authorOzcicek, Fatih
dc.contributor.authorKara, Ali Veysel
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorYazici, Gulce Naz
dc.contributor.authorÇoban, Abdulkadir
dc.contributor.authorSuleyman, Bahadır
dc.contributor.authorMammadov, Renad
dc.contributor.authorSuleyman, Halis
dc.date.accessioned2026-10-18T20:28:22.361066653Z
dc.date.available2026-10-18T20:28:22.361066653Z
dc.date.issued2020
dc.description.abstractPurpose: Vandetanib is a wide spectrum tyrosine kinase inhibitor used for the treatment of metastatic medullary thyroid cancer (MTC) and various other cancer types. Although it is usually well-tolerated ıt has been linked to a variety of severe dermatologic reactions. Our study aimed was to investigate adenosine 5′-triphosphate (ATP) on vandetanib-induced skin damage. Materials and methods: A total number of 18 rats were divided into three equal groups as vandetanib group (VDB), vandetanib plus ATP group (VAT), and healthy group (HG); 25 mg/kg ATP was injected intraperitoneally (ip) to the VAT group. Normal saline was given to the HG and VDB groups as solvent via intraperitoneally. One hour later, 25 mg/kg vandetanib was applied orally via an orogastric catheter in the VAT and VDB groups. This procedure was repeated once daily for 4 weeks. After that period, all animals were sacrificed and their skin tissues removed. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS) levels in rats’ skin tissues were evaluated with histopathological analyses. Results: MDA and TOS levels measured higher in the VDB group compared to the VAT and HG groups (p < 0.001). tGSH and TAS levels of the VDB group measured lower than the VAT and HG groups (p < 0.001). The structure and morphology of skin tissue were normal in the control group. In the VDB group, skin tissue damage with thinner epitelium, ruptured and degenerated hair follicles, abnormal accumulation of abnormal keratin on the epithelium and oedematous areas in the dermis was observed. In the VAT group, these findings were significantly improved. Conclusion: We demonstrated that adenosine triphosphate can prevent vandetanib-induced skin toxicity in rats for the first time. The promising results denote that further studies testing this agent in other animal models and in humans are warranted. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.doi10.1080/15569527.2020.1802742
dc.identifier.eissn1556-9535
dc.identifier.endpage327
dc.identifier.issn1556-9527
dc.identifier.issue4
dc.identifier.pmid32722951
dc.identifier.scopus2-s2.0-85089258970
dc.identifier.startpage323
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13540
dc.identifier.volume39
dc.identifier.wosWOS:000557610200001
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofCutaneous and Ocular Toxicology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectoxidative stress
dc.subjectrat
dc.subjectskin toxicity
dc.subjectVandetanib
dc.subjectAdenosine Triphosphate
dc.subjectAnimals
dc.subjectAntineoplastic Agents
dc.subjectGlutathione
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectPiperidines
dc.subjectProtein Kinase Inhibitors
dc.subjectQuinazolines
dc.subjectRats, Wistar
dc.subjectSkin
dc.subjectSkin Diseases
dc.subjectantioxidant
dc.subjectkeratin
dc.subjectmalonaldehyde
dc.subjectantineoplastic agent
dc.subjectN-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
dc.subjectpiperidine derivative
dc.subjectprotein kinase inhibitor
dc.subjectquinazoline derivative
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdermis
dc.titleEffects of adenosine triphosphate on vandetanib induced skin damage in rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus7
rdl.citation.wos7
rdl.departmentDepartment of Medical Oncology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Internal Medicine, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Histology and Emryology, Faculty of Science and Art, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)